Should Xpert® MTB/RIF be rolled out in low-income countries?

International Journal of Tuberculosis and Lung Disease

Volumn 16, Issue 5, 2012, Pages 702-703

  Peters, Dean ^a   Theron, Grant ^b   Peter, Jonny ^b   Dheda, Keertan ^b,c  

^a LONDON SCHOOL OF ECONOMICS   (United Kingdom)

^b UNIVERSITY OF CAPE TOWN   (South Africa)

^c UNIVERSITY OF CAPE TOWN   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

DIAGNOSTIC ACCURACY; HUMAN; LETTER; LOW INCOME COUNTRY; LUNG TUBERCULOSIS; MOLECULAR DIAGNOSIS; MORTALITY; MULTIDRUG RESISTANT TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; PRIORITY JOURNAL; PUBLIC HEALTH; SOCIETY; SOCIOECONOMICS; SOUTH AFRICA; SPUTUM CYTODIAGNOSIS; SPUTUM SMEAR; TREATMENT RESPONSE;

ANTITUBERCULAR AGENTS; HUMANS; NUCLEIC ACID AMPLIFICATION TECHNIQUES; RIFAMPIN; TUBERCULOSIS;

EID: 84859708366     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: 10.5588/ijtld.12.0034     Document Type: Letter

References (5)

1. Trébucq A, Enarson D, Chiang C-Y, et al. Xpert® MTB/RIF for national tuberculosis programmes in low-income countries: when, where and how? Int J Tuberc Lung Dis 2011; 15: 1567-1571.
2. World Health Organization. Global tuberculosis control 2011. WHO/HTM/TB/2011.16. Geneva, Switzerland: WHO, 2011.
3. Singh J A, Bhan A. The ethics of national tuberculosis programmes in low-income countries not rolling out Xpert® MTB/RIF [Editorial]. Int J Tuberc Lung Dis 2011; 15: 1563.
4. Dheda K, Shean K, Zumla A, et al. Early treatment outcomes and HIV status of patients with extensively drug-resistant tuberculosis in South Africa: a retrospective cohort study. Lancet 2010; 375: 1798-1807.
5. Streicher E M, Müller B, Chihota V, et al. Emergence and treatment of multidrug resistant (MDR) and extensively drug-resistant (XDR) tuberculosis in South Africa. Infect Genet Evol 2011; Aug 4 (e-pub ahead of print).